Proteasome inhibitors: all 957 studies that test it

Page 10 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive LymphomaTerminatedNCT00093704Phase 1
• Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy IICompletedNCT00093028Phase 3
• Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease ActivityActive, not recruitingNCT00092222Phase 2
• Bortezomib in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00091117Phase 1
• Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple MyelomaCompletedNCT00088855Phase 2
• VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT00085696Phase 2
• Study of Combination PS-341 and Thalidomide in Multiple MyelomaCompletedNCT00083460Phase 1
• Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00082966Phase 2
• Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell NeoplasmsCompletedNCT00082784Phase 1
• Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple MyelomaCompletedNCT00080405Phase 1
• Bortezomib in Treating Young Patients With Refractory or Recurrent LeukemiaCompletedNCT00077467Phase 1
• Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00077441Phase 2
• Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckCompletedNCT00077428Phase 2
• Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00075751Phase 2
• Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaCompletedNCT00074009Phase 2
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT00068315Phase 1
• Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyCompletedNCT00068289Phase 2
• Oxaliplatin and Bortezomib in Treating Patients With Advanced CancerTerminatedNCT00066625Phase 1
• Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To ChemotherapyCompletedNCT00066508Phase 2
• Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or UreterCompletedNCT00066352Phase 2
• Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsTerminatedNCT00064636Phase 1
• Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate CancerCompletedNCT00064610Phase 1/2
• A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039CompletedNCT00063726Phase 3
• VELCADE in Subjects With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00063713Phase 2
• Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus MitoxantroneCompletedNCT00059631Phase 1
• PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube CancerCompletedNCT00059618Phase 1
• Bortezomib in Treating Patients With Advanced Cancer and Kidney DysfunctionCompletedNCT00054483Phase 1
• Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic CancerCompletedNCT00052689Phase 2
• Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal CancerCompletedNCT00052507Phase 2
• Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00052338Phase 1
• Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal CarcinomaCompletedNCT00051987Phase 2
• Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00051974Phase 2
• PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00048230Phase 3
• Bortezomib in Treating Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00045695Phase 2
• Bortezomib in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT00040768Phase 2
• Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With ChemotherapyCompletedNCT00038571Phase 2
• Bortezomib in Treating Patients With Mantle Cell LymphomaCompletedNCT00030875Phase 2
• Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00030368Phase 1
• Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00028912Phase 1
• PS-341 in Treating Women With Metastatic Breast CancerCompletedNCT00028639Phase 2
• Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid TumorsCompletedNCT00027898Phase 1
• Bortezomib in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT00027716Phase 2
• PS-341 in Treating Women With Metastatic Breast CancerCompletedNCT00025584Phase 2
• PS-341 in Treating Patients With Metastatic Kidney CancerCompletedNCT00025376Phase 2
• PS-341 in Treating Patients With Metastatic Malignant MelanomaCompletedNCT00024011Phase 2
• Bortezomib in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00023881Phase 2
• Bortezomib in Treating Children With Advanced Solid TumorsCompletedNCT00021216Phase 1
• PS-341 in Treating Patients With Metastatic Kidney CancerCompletedNCT00017329Phase 2
• PS-341 in Treating Patients With Metastatic Neuroendocrine TumorsCompletedNCT00017199Phase 2
• PS-341 and Radiation to Treat Advanced Cancer of the Head and NeckCompletedNCT00011778Phase 1
• Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00007878Phase 1
• Bortezomib in Treating Patients With Recurrent GliomaTerminatedNCT00006773Phase 1
• PS-341 in Treating Patients With Advanced CancerCompletedNCT00006362Phase 1
• PS-341 in Treating Patients With Hematologic CancerCompletedNCT00006098Phase 1
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• PS-341 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00004002Phase 1

← Proteasome inhibitors overview